Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 14.5 | 68 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 14.0 | 64 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 15.0 | 60 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 10.0 | 63 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 19.0 | 63 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 12.0 | 78 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 16.0 | 55 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 143.0 | 53 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 447.5 | 42 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 425.0 | 53 | |
N2759 | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 547.5 | 62 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 471.0 | 49 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 535.5 | 64 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 194.0 | 57 | |
N2586 | IL-1 alpha | 100 | ng/mL | 3 | IP-10 | 212.0 | 57 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 40.0 | 43 | |
RA1869 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 43.0 | 59 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 21.0 | 59 | |
N2759 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 35.0 | 52 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 30.5 | 52 | |
RA1931 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 51.0 | 44 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 26.0 | 59 | |
N2586 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 37.5 | 64 | |
RA1869 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | IP-10 | 2315.5 | 58 | |
RA1869 | TNF-a | 100 | ng/mL | 3 | IP-10 | 5810.5 | 48 |